Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to si...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Beyond the Drug: How Human Factors Shape CVOT Success
ICON experts, Dr Emad Basta and Dr. Jack L Martin discuss how cardiovascular outcomes trials (CVOTs) are essential to ensuring drug safety, regulatory compliance, and clinical impact in this new article. Please find ICON's piece on page 24-25.
-
New ICON survey shows sites face growing delays and communication gaps during study startup
ICON’s survey of more than 100 investigators and site leaders reveals persistent bottlenecks in study startup driven by contract and budget delays, slow activation timelines, and insufficient collaboration from sponsors and CROs.
-
Research paints China as ‘global innovation powerhouse’
ICON’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.
-
China becoming dominant force in biotech sector, survey says
Chinese biotech dominance and opportunities for Western companies to stay competitive have been highlighted in surveys released by clinical research organization ICON.
-
The CRA role’s co-evolution with clinical trial technology
As clinical trials become more complex, the role of the CRA is evolving from site monitor to strategic, digitally fluent partner, requiring expertise in hybrid oversight, risk-based monitoring, and multi-system data management.
-
Accelerating timelines and reducing cost in early clinical drug development
Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to simplify complexity and speed timelines. This article discusses how the integration of science, technology and strategic insight can transform challenges into opportunities for breakthrough success.
-
Bold moves
CRAs are at the centre of clinical trial evolution. Risk-based monitoring, intelligent oversight tools and AI are changing how trials are managed. ICON explores what this means for the future in Pharma Times.
-
Transforming central labs with automation and AI: setting new standards for modern trials
Demands on central laboratories are consistently increasing, heightening the challenge to deliver operational excellence and the highest standard of scientific integrity with both speed and agility. ICON Laboratories is transforming the way we leverage data and intelligent operational models to meet evolving trial needs.
-
Investing in Anti-HIV: How Anti-HIV Therapeutic Developers Can Reshape the Future of HIV Control
Despite decades of progress transforming HIV from a fatal diagnosis into a manageable chronic condition, today’s antiretroviral therapies still face a stubborn barrier: They work brilliantly in theory but fall short when access, adherence, and real-world challenges get in the way.
-
Formulation Strategies, Tech Advances, Challenges and Considerations in Novel Drug Delivery
The transformative impact of complex biopharmaceuticals hinges on integrating advanced delivery systems, often accelerated by AI modeling, with robust manufacturing practices and regulatory alignment to ensure stability, safety, and effective patient access.
